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ABSTRACT
Background: The aim of  this study was to determine the effect of  initial therapy with 
some disease modifying antirheumatic drugs (DMARDs) (Methotrexate and Keto-
profen) on glomerular and tubular integrity in patients with Rheumatoid arthritis (RA). 
Objectives: To determine whether there is a change in clinical and laboratory indicators 
of  renal function in course of  the follow up of  treatment and whether that change 
correlates with the dynamics of  the quantity of  enzymes excreted in urine and reac-
tants of  the acute phase.
Materials and Methods: Using colorimetric method for determination of  NAG, samples 
of  70 participants were examined (35 RA patients treated with Ketoprofen only, 35 
RA patients treated with combined use of  Methotrexate and Ketoprofen). The follow 
up was 5 time-intervals in the course of  24 weeks. 
Results: There was moderate correlation between NAG and microalbuminuria (r=0,34) 
in the group of  patients treated with Ketoprofen only, while statistically signiﬁcant 
correlation (r=0,21) was seen in group of  patients with combined use of  Methotrex-
ate and Ketoprofen. NAG enzymuria in size, number of  patients registered, and time 
of  appearance were greater and appears earlier in the group with the combined use 
of  Methotrexate and Ketoprofen compared with the mono-therapy with Ketoprofen. 
Mean urinary NAG induction was increasing with the concomitant use of  Methotrex-
ate and Ketoprofen. 
Conclusions: Methotrexate is more potent NAG inductor than Ketoprofen and pro-
vokes greater tubular enzymuria than Ketoprofen.
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Implication for health policy/practice/research/medical education:
Determination of  the urinary N-acetyl-β-D-glucosaminidase together with the urinary creatinine excretion 
could serve as a more sensitive test for renal lesions in patients suffering from rheumatoid arthritis, as an ad-
ditional diagnostic tool, and the information for the status of  the disease. 
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1. Background
 raditional treatment of  rheumatoid ar-
thritis (RA) includes non-steroid anti-in-
ﬂammatory drugs (NSAIDs), drugs that 
modify the disease (DMRADs), steroids and im-
munosuppressive cytotoxic drugs.
 Methotrexate in low dose regimen is the most 
subscribed drug of  the DMRADs, while in the 
group of  NSAIDs Ketoprofen is the usually 
prescribed. Lysosomal system of  the tubules is 
dynamic system, and low level of  lysosomal en-
zymes, found in normal urine, is result of  normal 
exocytotic and pinocytotic activity of  the tubular 
endothelial cells (1). Enzymuria depends on the 
place and intensity of  damage. Increased enzyme 
activity is a reﬂection of  disease activity and re-
sidual functional capacity of  kidney (2). Pertur-
bation in renal tubules initially affects lysosomal 
membrane system in cells, resulting in increased 
loose of  enzyme in the urine in early stadium. 
Latter increase of  enzyme excretion is connect-
ed to structural damage of  cells resulting in cell 
necrosis. With the absence of  the toxic stimulus, 
decrease of  the urinary enzyme activity will be 
followed by regeneration of  tubular cell function.
 Criteria that make urinary enzymes suitable 
for determination of  certain abnormalities in re-
nal function are:
1. Low level of  enzymes in physiologic condi-
tions.
2. Sensitive methods for determination of  en-
zyme activities in urine.
3. High concentration of  examined enzymes in 
renal tissue.
4. Visible increase of  enzyme activity in urine in 
renal damage.
 Increase of  urine enzyme activity could show 
the place of  the primary renal tubular damage 
because of  their localization in brush border 
region (microsomal alanine amino peptidase 
(AAP), E.C.3.4.11.2) and tubular lysozymes 
(NAG E.C.3.2.1.30). They can be useful in early 
diagnose of  acute renal damage as nephrotoxic-
ity caused by immunosuppressive drugs, contrast 
substances, antibiotics and cadmium exposition 
(3-10). Urinary enzyme activity normally is very 
low in urine and is increased in renal tubular cell 
damage (11). Urinary enzymes, especially N-Ace-
tyl-β-D-glucosaminidase (NAG), AAP and Alka-
line Phosphatase (AP) are very sensitive indica-
tors of  renal parenchymal damage in comparison 
with functional measurements as GFR, creatinine 
and inulin clearance. Relatively low sensitivity of  
GFR could be explained with great functional 
reserve of  the kidney and its great capability of  
compensation. The use of  urinary enzymes is 
relatively simple, cheap, quick and non-invasive 
method in detection of  disease early stadium and 
renal failure follow up. In last 30 years a great 
attention has been paid in evaluation of  urinary 
enzymes as non-invasive markers for determina-
tion of  tubular damage. Urinary activity of  NAG 
is one of  the most evaluated urinary enzymes and 
is very sensitive marker for renal tubular damage 
(12, 13).
 Dosing of  most drugs must be adapted in renal 
insufﬁciency, making accurate assessment of  renal 
function an essential component of  diagnostics in 
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clinical medicine. Furthermore, even modest im-
pairment of  renal function has been recognized as 
a cardiovascular risk factor. As the most commonly 
used marker of  renal excretory function, serum cre-
atinine concentration, does not adequately respond 
to mild or moderate impairment of  renal function. 
More sensitive markers for renal excretory func-
tion are urgently seeked, especially in mild stages 
of  renal impairment. Symmetric dimethyl arginine 
(SDMA) is a methylated derivative of  the amino 
acid L-arginine. SDMA is eliminated from the body 
exclusively by renal excretion, therefore, SDMA 
plasma concentration is tightly related to renal 
function. Thus, quantiﬁcation of  plasma SDMA is 
an adequate mean to assess renal function, as could 
be demonstrated in a series of  recent clinical trials. 
In 18 clinical studies involving more than 2,100 pa-
tients’ systemic SDMA concentrations were highly 
correlated with inulin clearance as well as with vari-
ous clearance estimates and better corresponded to 
mild renal function impairment than serum creati-
nine. Thus, SDMA exhibits properties of  a reliable 
marker of  renal function. Furthermore, there is 
evidence showing that elevated SDMA level, which 
usually occurs in renal function impairment, may 
prospectively indicate future risk of  cardiovascular 
disease and mortality independentl of  the level of  
renal impairment (14-16).
1.1. Renal damage in Methotrexate and Ketoprofen use
 Possible mechanism of  Methotrexate nephro-
toxicity could be due to the interference of  nor-
mal lysosomal digestion which causes lysis of  the 
lysosomal membrane, pass of  the acid hydrolases 
in cell cytosol of  the proximal tubules, manifested 
latter with necrotic changes. Possible pathways of  
entrance in epithelial cells of  proximal tubules are:
1. Apical membrane transport with pinocytosis 
with adequate drug attachment (cytostatics, ami-
noglycosides, cephalosporins, diuretics and other 
toxic substances) inside lysosomes.
2. Apical membrane transport, which in some 
unknown way ﬁll in the process of  pinocytosis.
3. Baso-lateral membrane transport.
 If  Methotrexate is transported in proximal tu-
bular cells with pinocytosis, the hypothesis could 
be conﬁrmed that nephrotoxicity caused by it, is 
a result of  lysosomal dysfunction as the direct 
result of  its sedimentation in lysosomes. Vacu-
oles fulﬁlled with proteins are transported to the 
middle part of  the cell where are connected with 
previously existing lysosomes. Hydrolytic en-
zymes catalyze it, and newly formed products are 
suitable for re-circulation. In the mechanism of  
Methotrexate nephrotoxicity two moments are 
important: 
1. Active secretion in proximal tubular spaces 
with the same degree of  re-absorption.
2. Active transport inside in proximal tubu-
lar cells from the anti-luminal side with limited 
movements in tubular liquids.
It is proved that the toxic agents could pass 
through the cell membranes entering in lyso-
somes in non-ionized form, captured by acid pH 
in these organelles (17). There is possibility for 
Methotrexate to block the key lysosomal degra-
dation function, which leads to accumulation of  
the toxic product ordeterioration of  vital metab-
olism inside cells.
1.2. Some pharmacological aspects of  kinetics and dynamics of  
Methotrexate and Ketoprofen
1. Methotrexate only in 50-60% is attached to 
the plasma proteins. Increase in free Methotrex-
ate depends on the competition for albumin with 
other drugs with greater afﬁnity for attachment 
with albumin as aspirin or somr other NSAIDs 
and sulfonamides. 
2. Ketoprofen and Methotrexate are competing 
for attachment with plasma proteins, and their 
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concomitant use leads to increase in the non-al-
lied-free Methotrexate and signiﬁcant increase of  
its toxicity (18).
3. Excretion of  Methotrexate as free or its metab-
olite is through the kidneys i.e. through glomerular 
ﬁltration and proximal tubular secretion. Organ 
acids as phenylbutasone, penicillin, sulfonamides, 
salicylates, probenecid and NSAIDs (fenoprofen, 
naproxen, tolmetin) (19,20) competitively inhibit 
tubular secretion inﬂuencing Methotrexate clear-
ance. Toxic effects of  Methotrexate on normal 
tissue are more connected with the length of  ex-
position than with the level of  dose. 
 There are opposite results from the mutual 
interaction of  co-administration of  low dose of  
Methotrexate and other NSAIDs in patients suf-
fering from RA. Some reports suggest that there 
is no signiﬁcant interaction from the combined 
use of  low dose Methotrexate with piroxicam, 
naproxen and sulindac, but others suggest pos-
sible interaction in patients who suffer from RA 
treated with naproxen and ibuprofen (21-31), 
which needs the problem to be solved. Impair-
ment of  the renal function is noted in patients 
suffering from malignant diseases treated with 
high doses of  Methotrexate, but it is unknown 
whether administration of  low dose of  Metho-
trexate could manifest similar effects.
 
2. Objectives
 To determine whether there is a change in 
clinical and laboratory indicators of  renal func-
tion in course of  the follow up of  treatment and 
whether that change correlates with the dynamics 
of  the quantity of  enzymes excreted in urine and 
reactants of  the acute phase.
3. Patients and Methods
3.1. Patients
 In the patients examined for this study, the di-
agnosis of  the disease was established on the basis 
of  revised diagnostic criteria for the classiﬁcation 
of  RA, suggested in 1987 by the American Asso-
ciation for Rheumatism (ARA) (32). In order for 
a patient to be diagnosed with rheumatoid arthri-
tis, he or she must fulﬁll at least four out of  seven 
criteria. Criteria from one to four are present for 
at least six month. In this study 70 patients are ex-
amined, divided in 2 groups. In the group treated 
with Ketoprofen only are included 35 patients 
with RA. Of  them 27 (77%) are women, 8 (23%) 
are men. Mean age of  patients in this group is 
53.7±10.4 years (min=28, max=65 years). The 
disease lasted mean 72.2±52.7 months (min=1, 
max=360 months). In the group with combined 
use of  Methotrexate and Ketoprofen are in-
cluded 35 patients with RA. Of  them 29 (83%) 
are women, and 6 (17%) are men. Mean age of  
patients in this group is 53.9±9.7 years. The dis-
ease lasted mean 121.3±109.3 months (min=3, 
max=456 months).None of  the patients included 
in this study has medical record for past or pres-
ent renal disease. 6 patients are previously treated 
with oral steroids in the group of  patients treated 
with combined use of  Methotrexate and Keto-
profen before the beginning of  follow up. Ste-
roids as bridge therapy in combined use of  these 
two drugs are not used during follow up. The rest 
negate use of  previous NSAIDs, golden salts and 
other drugs, especially antibiotics before use of  
Ketoprofen and Methotrexate. Samples are col-
lected in the period of  2 years.
3.2. Criteria for inclusion
 The study included patients suffering from 
RA, age 18-65 years, not treated with NSAIDs or 
DMARDs. 
3.3. Criteria for excluded from the research
 From the research were excluded all the patients 
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with a disease or condition which could directly or 
indirectly inﬂuence a change in results including:
1. Patients with previous medical record for dis-
eases of  the spleen, thyroid gland, hepatic dam-
age, renal, hematologic, cardiovascular, neurolog-
ic, lung damage, autoimmune diseases, AIDS and 
aged <18 years.
2. Patients with diabetes mellitus, acute infec-
tions, malignant neoplasm and febrile conditions.
3. Patients treated with antibiotics and salicylate 
in the period of  six months prior to the begin-
ning of  the study.
4. Patients with hypertension, gouty arthritis, in-
fections, SLE, Sjögren, mixed conjunction tex-
ture disease and vasculitis.
5. Patients treated with antihypertensive or anti-
diabetic drugs.
6. Patients with anamnesis for transfusion of  
blood and overweight.
7. Hypersensitive to some of  the medicines or 
their components.
3.4. Clinical evaluation of  disease activity
 A subspecialist in this ﬁeld did the clinical 
evaluation. The activity of  the disease was evalu-
ated using DAS 28 index (33-36). The index is 
a mathematical formula that allows us to get a 
uniquely composed quantitativescore, which 
constitutes from palpation painful sensitive joints 
(max number 28), swollen joints (maxnumber 
28), Westergren ESR, and the patient’s global as-
sessment of  the activity of  disease (0–100 mm 
Visual Analogous Scale, (VAS)) and the morning 
rigid (minutes). DAS 28 index is ranked from 0 to 
10 and a score under 3.2 ranks the disease as low-
active. The assessment of  GFR was calculated 
using the Cockroft-Gault equation
3.5. Laboratory assessment
 For clinical estimation of  the disease it was 
necessary to take in consideration following lab-
oratory variables: blood count, differential, reac-
tants of  the acute phase: CRP, RF and ESR, an-
ti-CCP 2 antibodies, alkaline phosphatase (AP), 
aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), creatine kinase (CK), lac-
tate dehydrogenase (LDH), urea and creatinine in 
serum.  Examples of  urine were taken not only 
for routine urine analysis, but also for detection 
of  NAG, creatinine in urine and microalbumin-
uria. For processing are used samples from sec-
ond urine, not frozen, immediately processed, 
preserving the rules for good laboratory practice.
3.6. ELISA technology of  DLD-Diagnostika-GMBH for 
detection of  symmetric dimethyl arginine (SDMA)
Principle of  the assay
 The competitive SDMA-ELISA uses the mi-
cro titer plate format. SDMA is bound to the 
solid phase of  the micro titer plate. SDMA in 
the samples is acylated and competes with solid 
phase bound of  SDMA for a ﬁxed number of  
rabbit anti-SDMA antiserum binding sites. When 
the system is in equilibrium, free antigen and free 
antigen-antiserum complexes were removed by 
washing. The antibody bound to the solid phase 
SDMA was detected by anti-rabbit/peroxidase. 
The substrate TMB/peroxidase reaction was 
monitored at 450 nm. The amount of  antibody 
bound to the solid phase SDMA was inversely 
proportional to the SDMA concentration of  the 
sample.
Reference value: 0,3-0,7μmol/L
3.7. Colorimetric assay for the determination of  n-acetyl-β-d 
glucosaminidase (NAG) in urine (ROCHE)
Principle of  the assay
3-Cresolsulfonphthaleinyl-N-Acetyl-β-D-
glucosaminide, sodium salt, was hydrolyzed by 
N-Acetyl-β-D-glucosaminidase (NAG) with the 
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release of  3-cresol-sulfonphthalein, sodium salt 
(3-cresol purple), which was measured photo-
metrically at 580nm using Roche Mancheim tests. 
Turbid urines centrifuged and the supernatant 
was decanted. Reference value: NAG urine 0.27-
1.18 U/mmol creatinine.
3.8. Immunoturbidimetric assay for the determination of  urinary 
albumin (RANDOX LABORATORIES LIMITED)
Principle of  the assay
 An undiluted sample was added to a buffer 
containing the antibody speciﬁc for human se-
rum albumin. The absorbance (340 nm) of  the 
resulting turbid solution was proportional to the 
concentration of  albumin in the sample urine. By 
constructing a standard curve from the absor-
bance of  standards, the albumin concentration 
was determined. The assay carried out manually 
(at room temperature) (37, 38).
Sample collection and storage
 For random urinary albumin measurement, 
an early morning mid-stream specimen was used. 
The samples were centrifuge before use and ana-
lyzed the clear supernatant in the assay. 
Reference value: 2.0-20.0 mg/L.
3.9. Urea in serum
 Urea was detected with the method of   «Kas-
sirer». Reference values are 3–7.8 mmol/L.
3.10. Creatinine in serum and urine
 Creatinine was detected with the «Jaffe» meth-
od. Reference value for creatinine in serum is 45-
109 μmol/L and for creatinine in urine is 7-17 
μmol/dU.
3.11. Rheumatic factor (RF)
 RF was determined using the test of  aggluti-
nation (Latex RF test) (BioSystems S.A. Reagents 
& Instruments Costa Brava 30, Barcelona, Spain). 
Reference values is under 8 mg/L RF in serum.
3.12. C-reactive protein (CRP)
 CRP was found using the test of  agglutination 
(Latex CRP test), (BioSystems S.A. Reagents & 
Instruments Costa Brava 30, Barcelona, Spain). 
Reference value is under 6 mg/L CRP in serum.
3.13. Red cell sedimentation (ESR)
 For measurement of  ESR we used the meth-
od of   Westergren, and normal values were: for 
male patients, 7–8 mm and for female patients, 
11–16 mm.
3.14. Statistical Analysis
 Student’s t test was used for testing the differ-
ence between two arithmetic means comparing 
two groups, and Wilcoxon-matched test was used 
for independent examples. The association be-
tween various group data was calculated with the 
Pearson or Spearman rank correlation tests for 
parametric and non-parametric data respectively. 
Analysis of  relation between attributive statistical 
series was made with Pearson’s χ2 test. Test of  
the signiﬁcance of  the differences among three 
or more arithmetical means was made with Anal-
ysis of  variance (ANOVA); as well as Freedman’s 
analysis of  variance (Frχ2). Statistical series are 
shown with tables and ﬁgures according to the 
deﬁned variables of  interest. Statistical software 
Stata, release 7.0 for data processing was used. 
Data are expressed as Mean+SD and range when 
appropriate. P values less than 0.05 were consid-
ered signiﬁcant.
4. Results
 Analyzing the distribution of  patients accord-
ing to the values of  NAG in the ﬁve probes, in 
the group of  patients treated only with Ketopro-
Spasovski D et al
Journal of  Nephropathology, Vol 2, No 1, January 2013        www.nephropathol.com42
fen, one could conclude that evaluated values of  
NAG are registered in 27 (77%) of  patients in 
16th week (4th probe), when mean urinary NAG 
induction is the highest (1.65±0.74).
 But, analyzing the group of  patients treated 
with combined use of  Methotrexate and Keto-
profen, in relation with the distribution of  pa-
tients according to the values of  NAG in the ﬁve 
probes, one could conclude that elevated values 
of  NAG are registered in 31 (89%) of  patients in 
the 8th week (3rd probe), when the degree of  mean 
urinary NAG induction is highest (1.99±1.00).
 Testing the signiﬁcance in differences in both 
groups in 0 spot, in the group of  patients treat-
ed only with Ketoprofen, the mean value of  the 
urinary NAG induction ranges 0.93±0.48, in the 
group of  patients treated with combined use 
of  Methotrexate and Ketoprofen 1.13±0.54. It 
shows that Methotrexate is more potent NAG 
inductor compared with Ketoprofen, but during 
their combined use, the mean urinary NAG in-
duction is increased considering size and time of  
appearance (Table 1, Figures 1 and 2).
 In the group of  patients treated with Keto-
profen, the distribution of  patients according 
to the values of  microalbuminuria in the ﬁve 
probes, one could conclude that elevated values 
of  microalbuminuria are registered in 7 (20%) of  
patients in the 4th week (2nd probe) when the level 
of  microalbuminuria is highest (19.55±11.46).
 Analyzing the distribution of  patients accord-
ing to the values of  microalbuminuria in the ﬁve 
probes, in the group of  patients treated with the 
combined use of  Methotrexate and Ketoprofen, 
we can conclude that increased values of  micro-
albuminuria above normal range are maximally 
registered in 10 (29%) of  patients in the 8th week 
(3rd probe) with size of  induction 20.50±9.69 
(Table 1, Figures 3 and 4).
 Testing the signiﬁcance of  difference in both 
groups in 0 spot, in the group of  patients treated 
with Ketoprofen only, the mean value of  microal-
buminuria is 17.91±11.17, while in the group treat-
ed with combined use of  Methotrexate and Keto-
profen the mean value is 16.35±7.41. This explains 
why Methotrexate gives identical appearance of  
microalbuminuria compared with Ketoprofen, but 
with their combined use microalbuminuria is in-
creased both in size and time of  appearance.
 Analysis with Pearson’s χ2 test showed that 
there was moderate correlation between NAG 
and microalbuminuria in the ﬁve probes in the 
period of  24 weeks in the group of  patients treat-
ed only with Ketoprofen.
 Analysis with Pearson’s χ2 test showed that there 
was statistically signiﬁcant correlation (r=0.21) be-
tween the elevation of  values of  NAG and micro-
albuminuria in the ﬁve probes in the period of  24 
weeks in the group with combined use of  Metho-
trexate and Ketoprofen (Figures 5 and 8).
4.1. SDMA, NAG, microalbuminuria and reactants of  the 
acute phase
 Considering the reactants of  the acute phase, 
CRP and RF, in the group of  patients treated only 
with Ketoprofen, Friedman’s analysis of  variance 
(Frχ2) showed that there were not statistically sig-
niﬁcant differences between mean values of  RF 
and CRP in the ﬁve probes: RF (465.12±261.27, 
Frχ2=0.9474; p=0.4380) and CRP (39.24±59.19, 
Frχ2=0.2693; p=0.8974).
 Analysis with Pearson’s χ2 test showed that 
there was statistically signiﬁcant correlation be-
tween the elevation of  NAG and RF in the ﬁve 
probes (χ2 =12.061, df=1, p=0.00052) But there 
was not statistically signiﬁcant correlation be-
tween the elevation of  microalbuminuria and RF 
in the ﬁve probes (χ2 =2.087, df=1, p=0.1484).   
 Analysis with Pearson’s χ2 test showed that 
there was statistically signiﬁcant correlation 
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Table 1.  NAG, microalbumin and other laboratory variables in the group of patients treated with Ketoprofen 
only, and in the group with combined use of Ketoprofen and Methotrexate
KETOPROFEN GROUP No 35 KETOPROFEN+METHOTREXAT GROUP No 
35
NAG
+ >1.18
(U/mmol/crea)
value (M ± SD)
normal range (%)  /
elevated values (%)
MICROALBU-
MINURIA
+ >20
(mg/L)
value (M ± SD)
normal range (%)  /
elevated values (%)
GFR NAG
+ >1.18
(U/mmol/crea)
value (M ± SD)
normal range 
(%)  /
elevated values 
(%)
MICROALBU-
MINURIA
+ >20
(mg/L)
value (M ± SD)
normal range (%)  /
elevated values 
(%)
GFR
0 
spot
1.13±0.54
22 (63%) / 
13(37%)
17.91±11.17
30 (86%)/ 5 (14%)
99.5±22.5 0.93±0.48
25 (71%)/ 10 
(29%)
16.35±7.41
30 (86%)/ 5 (14%)
95.9±32.6
4th 
week
1.27±0.48
17 (49%) / 18 
(51%)
19.55±11.46
28 (80%) /  7(20%)
99.9±24.1 1.27±0.47
18 (51% ) / 17 
(49%)
18.21±7.63
26 (74%) / 9 (26%)
97.1±39.4
8th 
week
1.49±0.67
12 (34%) /  23 
(66%)
18.91±13.03
30 (86%)/ 5 (14%)
102.9±30.1 1.99±1.00
4 (11%)/ 31 (89%)
20.50±9.69
25 (71%)/ 10 
(29%)
98.8±36.1
16th 
week
1.65±0.74
8 (23%) / 27 (77%)
18.08±11.68
32 (91%)/ 3 (9%)
101.2±25.5 1.94±1.02
10 (29%)/ 25 
(71%)
17.02±5.64
29 (83%)/ 6 (17%)
95.9±32.6
24th 
week
1.36±0.57
15 (43%) / 20 
(57%)
18.14±12.65
32 (91%)/ 3 (9%)
98.8±22.3 1.36±0.83
21 (60%)/ 14 
(40%)
14.74±8.56
32 (91%)/ 3 (9%)
98.9±44.3
 
 
Figure 1. Mean values of N-acetyl-β-D-glucosaminidase (NAG) in patients of the group treated with Ketoprofen only 
in the ﬁve probes
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Figure 2. Mean values of N-acetyl-β-D-glucosaminidase (NAG) in the group of patients with the combined use of  
Methotrexate and Ketoprofen in the ﬁve probes
Figure 3. Mean values of microalbuminuria in the group of patients treated with Ketoprofen only in the ﬁve probes
among the elevation of  NAG, microalbuminuria 
and CRP in the ﬁve probes in the follow up pe-
riod; NAG vs. CRP (χ2 =5.453, df=1; p=0.0195). 
Microalbuminuria vs. CRP (χ2 =6.377, df=1; 
p=0.0115).
 Considering SDMA, analysis with Pearson’s χ2 
test showed that there was not statistically signiﬁ-
cant correlation between the elevation of  NAG 
and SDMA (χ2 =2.127, df=1, p=0.01446); as 
well as microalbuminuria vs. SDMA (χ2=0.1307, 
df=1, p=0.9983).
 With combined use of  Methotrexate and Ke-
toprofen in respect to RF and CRP, Frχ2 showed 
that there was not statistically signiﬁcant correla-
tion between the mean values of  RF and CRP 
in the ﬁve probes RF(448.76±427.5, Frχ2=0.676, 
p=0.6091) and CRP (54.1±48.0, Frχ2=0.334, 
p=0.8552).  
 Analysis with Pearson’s χ2 test showed that 
there was statistically signiﬁcant correlation be-
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Figure 4. Mean values of microalbuminuria in the group of patients with the combined use of Methotrexate and Keto-
profen in the ﬁve probes
Figure 5. Pearson’s coeﬁcient of correlation (r) between the values of N-acetyl-β-D-glucosaminidase (NAG) and micro-
albuminuria in the group of patients treated with Ketoprofen only
There is moderate correlation between NAG and microalbuminuria (r=0,34).
Figure 6. Pearson’s coeﬁcient of correlation (r) between the values of N-acetyl-β-D-glucosaminidase (NAG) and micro-
albuminuria in the group of patients with the combined use of Methotrexate and Ketoprofen
There is signiﬁcant correlation between NAG and microalbuminuria (r=0,21).
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Figure 7. Distribution of patients in the group treated with Ketoprofen only according to the elevated values of Sym-
metric dimethyl Arginine (SDMA), N-acetyl-β-D-glucosaminidase (NAG), microalbuminuria and other laboratory 
variables in the ﬁve probes
Figure 8. Distribution of patients in the group with the combined use of Methotrexate and Ketoprofen according to the 
elevated values of Symmetric dimethyl Arginine (SDMA), N-acetyl-β-D-glucosaminidase (NAG), microalbuminuria 
and other laboratory variables in the ﬁve probes
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tween the elevation of  NAG and RF in the ﬁve 
probes in the follow up period; NAG vs. RF 
(χ2=13.70, df=1, p=0.0021), but there was not 
between microalbuminuria and RF (χ2=2.389, 
df=1, p=0.1221). 
 Analysis with Pearson’s χ2 test showed that 
there was not statistically signiﬁcant correlation 
among the elevation of  NAG, microalbuminuria 
and CRP in the ﬁve probes in the follow up pe-
riod; NAG vs. CRP (χ2=1.787, df=1, p=0.1812), 
microalbuminuria vs. CRP (χ2 =0.3714, df=1, 
p=0.542).
 With combined use of  Methotrexate and 
Ketoprofen in respect of  SDMA analysis with 
Pearson’s χ2 test with Yate’s correction showed 
that there was statistically signiﬁcant correla-
tion among the mean values of  NAG, micro-
albuminuria and CRP in the ﬁve probes in the 
follow up period, NAG vs. SDMA (χ2=4.353, 
df=1, p=0.0386), microalbuminuria vs. SDMA 
(χ2=4.061, df=1, p=0.0439) (Table 2).
4.2. SDMA, NAG, microalbuminuria and degradation 
products of  the nitric metabolism
 Considering the degradation products of  the 
nitric metabolism, serum creatinine, urine creati-
nine, serum urea, in the group of  patients treated 
only with Ketoprofen, Frχ2 showed that there 
was not statistically signiﬁcant correlation among 
the mean values of  all degradation products in 
the ﬁve probes. All patients, in all measurements 
had values in normal range. Creatinine/serum 
(66.89±14.02, Frχ2=0.0480, p=0.9956), creati-
nine/urine (5.26±1.63; Frχ2=0.4469, p=0.7745). 
 In the group of  patients with the combined 
use of  Methotrexate and Ketoprofen in the ﬁve 
probes, Frχ2 of  degradation products showed 
that there were not statistically signiﬁcant dif-
ferences among the mean values of  the degra-
dation products in the ﬁve probes. All patients 
in all measurements had values in normal range. 
Creatinine/serum (67.69±13.59, Frχ2=0.1424, 
p=0.9660), creatinine/urine (9.52±4.89, Frχ2 
=1.3263, p=0.2621); urea/serum (5.67±1.41, 
Frχ2=0.4454, p=0.7755). 
 In the group of  patients treated only with Ke-
toprofen, as well as in combined use of  Metho-
trexate and Ketoprofen, regarding serum creati-
nine, all patients in all measurements had values 
in normal range. Analysis of  variance (ANOVA) 
showed that there were not statistically signiﬁ-
cant differences between the mean values of  the 
serum creatinine in patients of  the two groups 
(F=0.684, p=0.5631). There was not statistically 
signiﬁcant correlation among the elevation of  
SDMA, NAG, and microalbuminuria and serum 
creatinine in the ﬁve probes. 
 Regarding urine creatinine, analysis with Pear-
son’s χ2 test with Yate’s correction showed that:
1. There was statistically signiﬁcant correlation 
between the elevation of  values of  NAG and 
urine creatinine in the ﬁve probes (χ2=5.887, 
df=1, p=0.0152), as well as between microalbu-
minuria and urine creatinine (χ2 =31.148, df=1, 
p=0.0001); but not during combined use Metho-
trexate and Ketoprofen. 
2. There was not statistically signiﬁcant correla-
tion between the elevation of  values of  NAG 
and urine creatinine in the ﬁve probes in the 
follow up period (χ2=1.050, df=1, p=0.3053). 
There was not statistically signiﬁcant correlation 
between the elevation of  values of  microalbu-
minuria and urine creatinine in the ﬁve probes 
(χ2=2.488, df=1, p=0.114). ANOVA showed 
that there were not statistically signiﬁcant differ-
ences between the mean values of  the urine cre-
atinine in patients of  the two groups (F=0.1611, 
p=0.9222).
 Considering serum urea in the two groups 
analysis with Pearson’s χ2 test with Yate’s correc-
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Table 2.  SDMA, NAG, microalbumin and other laboratory variables in the group treated with Ketoprofen 
only, and in the group with combined use of Ketoprofen and Methotrexate
KETOPROFEN 
GROUP
KETOPROFEN + METHOTREXAT
GROUP
M ± SD Fr χ2 p NAG MICROAL-
BUMIN-
URIA 
M±SD Frχ2 p NAG MICROAL-
BUMINURIA
CRP 39.24±59.19 0.2693 0.8974 Frχ2 =5.453
df=1,
p=0.0195*
Frχ2 = 6.377
df=1,
p=0.0115*
54.1±48.0 0.334 0.8552 Frχ2=1.787   
df=1
p=0.1812
Frχ2=0.3714
df=1
p=0.542
RF 465.12±261.27 0.9474 0.4380 Fr χ2 
=12.061
df=1
p=0.00052*
Frχ2  = 
2.087
df = 1
p = 0.1484 
448.78±427.5 0.676 0.6091 Frχ2=13.70   
df=1
p=0.0021* 
Frχ2=2.389     
df=1
p=0.1221
SDMA Frχ2=2.127
df=1
p=0.1446
Frχ2=0.1307
df=1
p = 0.9983
Frχ2=4.353   
df=1
p=0.0368*
Frχ2=4.061   
df=1
p=0.0439*
GFR 99.5±22.5 0.1521 0.9618 95.9±32.6 0.0551 0.9943
kreat-
inin / 
serum
66.89±14.02 0.0480 0.9956 67.69±13.59 0.1424 0.9660
kreat-
inin / 
urina
9.64±6.68 0.1196 0.9753 Frχ2=5.887
df=1
p=0.0152*
Frχ2=31.148 
df=1
p = 0.0001*
9.52±4.89 1.3263 0.2621 Frχ2=1.050   
df=1
p=0.3053
Frχ2=2.488   
df=1
p=0.114
urea / 
serum
5.26±1.63 0.4469 0.7745 Frχ2=0.0073
df=1
p=0.9316
Frχ2=2.407
df=1
p=0.1207
5.67±1.41 0.4454 0.7755 Frχ2=0.0637
df=1
p=0.8007
Frχ2=0.1148
df=1
p=0.7346
* statistically signiﬁcant differences
tion showed that in the group of  patients treated 
only with Ketoprofen there was not statistically 
signiﬁcant correlation between the elevation 
of  values of  NAG and urea in the ﬁve probes 
(χ2=0.0073, df=1; p=0.9316), as well as between 
microalbuminuria and serum urea (χ2=2.407, 
df=1, p=0.1207), as with the combined use 
of  Methotrexate and Ketoprofen: NAG vs. se-
rum urea in the ﬁve probes (χ2=0.1148, df=1, 
p=0.7346). ANOVA showed that there were not 
statistically signiﬁcant differences between the 
mean values of  the serum urea in patients of  the 
two groups: F=1.132, p=0.3384.
4.3. SDMA, NAG, microalbuminuriaand calculated creati-
nine clearance
 Frχ2 showed that there were not statistically 
signiﬁcant differences between the mean values of  
calculated creatinine clearance (CCC) in the ﬁve 
probes in the group of  patients treated only with 
Ketoprofen (Frχ2=0.1521; p=0.9618), as well in 
the group with combined use of  Methotrexate 
and Ketoprofen (Frχ2= 0.0551; p=0.9943).
 Analyzing the mean values of  CCC in the two 
groups in 0 probe, in patients treated only with 
Ketoprofen and in the group of  patients treated 
with combined use of  Methotrexate and Keto-
profen, ANOVA showed that there were not sta-
tistically signiﬁcant differences between the mean 
values of  the CCC in patients of  the two groups 
(F=0.130, p=0.9419). There was not statistically 
signiﬁcant correlation between the elevation of  
the mean values of  NAG, microalbuminuria and 
CCC in the two groups. (Tables 1 and 2).
5. Discussion
 In this study, the analysis with Pearson’s χ2 test 
showed that there was statistically signiﬁcant cor-
relation (r=0.21) between the elevation of  NAG 
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and microalbuminuria in the ﬁve probes in the 
follow up period of  24 weeks in the group with 
combined use of  Methotrexate and Ketoprofen, 
while there was moderate correlation between 
NAG and microalbuminuria (r=0.34) in the ﬁve 
probes in the follow up period of  24 weeks in the 
group of  patients treated with Ketoprofen only.
 Initial increase of  the activity is a result of  the 
changes in cell synthesis and not always enzymuria 
can be result of  the lytic or necrotic processes. 
However, with the appearance of  the second 
peak, one can be certain of  the necrotic process 
provoked by these drugs. Signiﬁcant elevation of  
the activity of  NAG is 2-3 times higher than the 
values gained in the probe with maximal induc-
tion (8th week) in combined use of  Methotrexate 
and Ketoprofen (0.93±0.48 vs 1.99±1.00) in cor-
relation with the isolated Ketoprofen (1.13±0.54 
vs 1.65±0.74) in the probe with maximal induc-
tion (16th week), without bi-phase appearance.
 Very important ﬁnding in the study, besides 
high frequency of  abnormal urinary excretion 
of  NAG is decrease of  the frequency of  high 
NAG values in the course of  the combined use 
of  Methotrexate and Ketoprofen. Signiﬁcant 
decrease of  the NAG excretion was noticed in 
the 24th week as a result of  the reduction of  the 
disease itself  by the favorable beneﬁcial effect of  
Methotrexate on inﬂammation, correlates with 
ESR, which is in concordance with the ﬁndings 
of  other authors (24-26, 29). The kidney is highly 
plastic organ and decrease of  NAG excretion is 
a result of  the adaptive characteristics of  the kid-
ney in the presence of  externalmatter.
 Lysosomal enzymes show expressible ten-
dency towards normalization. This probably 
is due to the regeneration processes which is 
proved on the level of  the tubular epithelium, 
also noticed by other authors (39,40). However, 
that is not the case with the membrane AAP, γ 
glutamyl transferase, γ-GT and AF, which after 
the treatment stay on high signiﬁcant levels in 
terms of  decreased activity. Regenerated tubular 
epithelium shows high resistance towards inﬂu-
ences of  drugs.
 Low doses of  Methotrexate regime did not 
cause signiﬁcant damage of  the renal proximal tu-
bules in the most of  the followed patients. Neph-
rotoxicity in the monotherapy with Methotrexate 
is bigger than with Ketoprofen. Methotrexate is 
more potent NAG inductor in comparison with 
Ketoprofen. The size of  the NAG enzymuria 
and microalbuminuria is bigger in monotherapy 
with Methotrexate in comparison with the iso-
lated use of  Ketoprofen, but especially mean uri-
nary NAG induction is increased with the con-
comitant use of  Methotrexate and Ketoprofen. 
NAG induction, in size, is bigger and appears 
earlier in combined use of  Methotrexate and Ke-
toprofen in comparison with the monotherapy 
with Ketoprofen. Early detection of  high NAG 
enzymuria or microalbuminuria before the treat-
ment with Methotrexate can be of  use consid-
ering the anticipation for possible Methotrexate 
toxicity probably connected with impaired renal 
clearance of  Methotrexate. Parameters as age of  
patients, duration of  disease in months, previous 
or current treatment, do not allow us to anticipa-
tethe decrease of  NAG enzymuria. 
 There is not any changes in the clinical param-
eters of  the renal function regarding degradation 
products of  the nitric metabolism (creatinine in 
serum and urine, GFR) in the course of  follow 
up. The least sensitive markers for early nephro-
toxicity caused by Methotrexate and Ketoprofen 
are concentration of  creatinine in serum and 
urine and urea in serum, as well as the level of  
CCC. These tests point at the changed, decreased 
glomerular ﬁltration, but not at the changes in 
renal tubular function. We think that the use 
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of  these parameters can ﬁnd application in the 
clinical practice in cases when there is much lon-
ger therapy with Methotrexate and Ketoprofen, 
combined with antibiotics, when they can indi-
cate impairment of  the glomerular ﬁltration.
6. Conclusions
 Determination of  the urinary NAG together 
with the urinary creatinine excretion could serve 
as a more sensitive test for renal lesions in pa-
tients suffering from RA, as an additional diag-
nostic tool, and the information for the status of  
the disease. Obtained results in this study con-
ﬁrmed the safety and efﬁcacy of  Methotrexate 
and Ketoprofen in treatment of  RA. Following 
the renal function with enzyme activity in urine 
for evaluation of  the effective metabolic exfol-
liative turnover of  tubular cells, avoidance of  the 
frequent use of  drugs, as well as individual adap-
tation of  the doses are measurements for avoid-
ance of  the nephrotoxicity of  these drugs.
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